Table 1. Results of cytology, biopsy, immunostaining, and HPV genotyping and treatment of cervical GCC.
Case | Age | FIGO stage | Cytology result | Biopsy result | Immunostaining result | HPV genotype | Treatment | ||||
---|---|---|---|---|---|---|---|---|---|---|---|
p40 | CEA | ER | PgR | p16 | |||||||
1 | 38 | IIB | Carcinoma, type undetermined | GCC | Negative | Negative | Negative | Negative | Block positive | HR HPV (type 18) detected | CCRT |
2 | 63 | IIB | Adenocarcinoma | GCC | Negative | Negative | Negative | Negative | Block positive | HR HPV (type 16) detected | CCRT |
3 | 36 | IIB | Unsatisfactory/GCC* | GCC | Negative | Negative | Negative | Negative | Block positive | HR HPV (type 31) detected | CCRT |
4 | 67 | IIIB | GCC | GCC | Negative | Negative | Negative | Negative | Block positive | HR HPV (type 18) detected | CCRT |
5 | 37 | IIB | Poorly differentiated carcinoma | GCC | Negative | Negative | Focal positive | Focal positive | Block positive | HR HPV (type 18) detected | CCRT |
Abbreviations: CCRT: concurrent chemoradiation therapy, CEA: carcinoembryonic antigen, ER: estrogen receptor; FIGO: International Federation of Gynecology and Obstetrics, GCC: glassy cell carcinoma, HPV: human papillomavirus, HR: high-risk, PgR: progesterone receptor;
At the time of recurrence